http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c#Head http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c#assertion http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c#provenance http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c#pubinfo http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c#assertion http://purl.obolibrary.org/obo/DOID_3083 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_3083 http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB01274 http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c#association http://www.w3.org/2000/01/rdf-schema#label brovana inhalation solution is a long acting beta 2 2 long term twice daily morning and evening administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease copd including chronic bronchitis and emphysema 1 1 important limitations of use brovana inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease 1 2 5 2 brovana inhalation solution is not indicated to treat asthma 1 2 brovana arformoterol tartrate inhalation solution is indicated for the long term twice daily morning and evening maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease copd including chronic bronchitis and emphysema brovana inhalation solution is for use by nebulization only brovana inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease see warnings and precautions 5 2 brovana inhalation solution is not indicated to treat asthma the safety and effectiveness of brovana inhalation solution in asthma have not been established http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c#association https://w3id.org/biolink/vocab/relation https://w3id.org/um/neurodkg/SymptomaticReliefIndication https://identifiers.org/drugbank:DB01274 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c#provenance http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c#pubinfo http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c#sig http://purl.org/nanopub/x/hasSignature SXanaorpvFl3Y6REgLcJHPLZNLq21w1Bi3V0X+LRHf/DjHGvaVk3ghanKEWOj00Hc1ud6xEBbJDrR2D0vCWG/ZtllDebmAYH548FioXERAeaSrIaCoav8vLXeoyG6OP60Qud6BpSBSRq8xDz5nt8u/WVw/+IEL5aNdFumc8NQSw= http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c http://purl.org/dc/terms/created 2021-06-12T13:24:21.725+02:00 http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAKpzZyDvGWlCZeIF6XuF9KeXIaJKI4cRQmBL8YA05c8c https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs